Compare Recursion Pharmaceuticals Inc (RXRX) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.65 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 22.2× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| RXRX | TLT | |
|---|---|---|
Market Cap | $2.14B | $47.61B |
Volume | 30,789,535 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $92.06 |
52-Week Low | $2.84 | $77.11 |
Typical Hold Time | 22 Days | 83 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.145, down 0.17% amid a challenging bond market environment. The technical picture is bearish with moving averages signaling strong selling pressure, though oscillators are neutral. Recent news highlights Treasury yields reaching multi-decade highs, with the fund experiencing significant outflows and declining nearly 50% over five years as rising interest rates pressure long-duration bonds.
The outlook remains pressured by persistent high interest rates and inflation concerns. While current yields above 5% offer income appeal, further rate hikes or prolonged elevated rates could extend the downtrend. Key risks include Federal Reserve policy uncertainty and economic data volatility. Investors should weigh the income potential against continued price depreciation risk in the current macro environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
